Evidence map›Paper›PMID 42709275›Full record

ArticleImmunologic research2026

USP19 facilitates CSE-induced cell damage and ferroptosis in chronic obstructive pulmonary disease by deubiquitinating HDAC6 to drive PRDX6 deacetylation.

Yingbo Yang, Jianmei Guo, Xiaoli Fu, Bolan Chai

Abstract read
PubMed Publisher
In one paragraph

Article in Immunologic research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yingbo YangDepartment of General Practice, Baoding First Central Hospital, Baoding, China.
Jianmei GuoDepartment of Outpatient, Baoding First Central Hospital, No. 320, Changcheng North Street, Lianchi District, Baoding, 071000, China. guojianmei19801115@163.com.
Xiaoli FuDepartment of Geriatrics, Baoding First Central Hospital, Baoding, China.
Bolan ChaiDepartment of General Practice, Baoding First Central Hospital, Baoding, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChronic obstructive pulmonary disease (COPD) is a disease characterized by airflow obstruction. Peroxiredoxin 6 (PRDX6) is vital in antioxidant defense and phospholipid metabolism, and linked to disease occurrence and progression. Ubiquitin-specific protease 19 (USP19), a deubiquitinating enzyme involved in protein stability regulation, has been implicated in inflammatory diseases and cellular stress responses, yet its role in COPD remains largely unknown. The objective of this study is to investigate the impact and the underlying mechanism of PRDX6 on cigarette smoke extract (CSE)-induced cell injury and ferroptosis, with a focus on the regulatory roles of USP19 and histone deacetylase 6 (HDAC6).

methodsThe expression levels of the genes were detected by reverse transcription-quantitative polymerase chain reaction (qRT-PCR) and western blot. The Cell counting kit-8 (CCK-8) was utilized to assess cell viability. Cell apoptosis was detected by flow cytometry. The levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) were detected using the enzyme-linked immunosorbent assay (ELISA). The iron ion (Fe2+), reactive oxygen species (ROS), and glutathione (GSH) kits were used to evaluate the ferroptosis index. The Biological General Repository for Interaction Datasets (BioGRID), Hitpredict database, and Ubibrowser database were used to predict protein interactions. Protein modifications and protein-protein interactions were verified using co-immunoprecipitation (CoIP). The treatment with cycloheximide (CHX) was used to verify protein stability. The rat COPD model was used for in vivo validation. Hematoxylin-eosin (HE), Masson's trichrome (Masson) and Periodic Acid-Schiff (PAS) staining were utilized for the assessment of lung injury. Immunohistochemistry (IHC) analysis was conducted to assess the levels of PRDX6 present in rat lung tissue.

resultsIn CSE-induced 16HBE cells, upregulating PRDX6 expression mitigated the decline in cellular viability, prevented apoptosis, suppressed inflammatory reactions, and halted ferroptosis. HDAC6 facilitated CSE-induced cellular damage and ferroptosis by mediating the deacetylation modification of PRDX6. USP19 enhanced the stability of HDAC6 by deubiquitination, thereby exacerbating CSE-induced cellular damage and ferroptosis. The elevated levels of PRDX6 mitigated cellular damage and ferroptosis in the rat COPD models.

conclusionsUSP19 modulates PRDX6 expression by deubiquitinating HDAC6, thereby promoting CSE-induced cellular damage and ferroptosis. This deepens our understanding on COPD pathogenic mechanism and may offer a new perspective for COPD treatment.

Indexed as

EndopeptidasesFerroptosisHistone Deacetylase 6Peroxiredoxin VIPulmonary Disease, Chronic ObstructiveAcetylationAnimalsCell LineHumansMaleRatsRats, Sprague-DawleyReactive Oxygen SpeciesSmokeUbiquitinationEndopeptidasesHDAC6 protein, ratHistone Deacetylase 6Peroxiredoxin VIPrdx6 protein, ratReactive Oxygen SpeciesSmokeChronic obstructive pulmonary diseaseCigarette smoke extractHDAC6PRDX6USP19

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.